The latest achievement by scientists from the PAS Institute of Bioorganic Chemistry and the Polish companies Polpharma, Medicofarma Future Synthesis and A&A Biotechnology, is a direct response to the needs of the public during the pandemic.
The SARS-CoV-2 and influenza viruses cause two different diseases whose symptoms may be similar but which require completely different management. At the same time, the winter season is characterized by seasonal spikes in infections, also including cases caused by other types of viruses. The development of a differential test thus comes as a natural research interest for scientists from Poznan.
The characteristic features of the MediPAN-COVID+Flu test
The MediPAN-COVID+Flu genetic test detects two SARS-CoV-2-specific genes and one specific gene each for influenza type A and B. The kit has been designed so that SARS-CoV-2 and the flu virus can be detected in a single reaction well. At the same time, it is equipped with swab accuracy control to avoid false negative results due to incorrect sampling.
What makes the test easy to use?
- Short reaction time (ca. 1 hour),
- Highly sensitive virus detection reactions (>99%),
- Simple interpretation of the result,
- Suitability for use with the same diagnostic equipment as tests which only detect SARS-CoV-2.
This is the second time this year that cooperation between the PAS, Polpharma and Medicofarma has shown that creative combination of scientific knowledge and business process expertise can lead to the creation of top quality products. It is important to note that besides its diagnostic value, understood as the ability to quickly detect the right disease, the MediPAN-COVID+Flu test fits perfectly well with WHO recommendations which stress the necessity to choose multiplex PCR tests for simultaneous detection of the influenza and SARS-CoV-2 viruses to ensure efficient use of reagents, consumables and staff working time.